2023 World Conference on Lung Cancer (Posters)-EP12.01. Treatment Strategies and Survival Outcomes of Patients with EGFR-mutated NSCLC and leptomeningeal metastasis

EP12.01. Treatment Strategies and Survival Outcomes of Patients with EGFR-mutated NSCLC and leptomeningeal metastasis - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to investigate the treatment regimens and clinical outcomes in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) and leptomeningeal metastasis (LM). The researchers retrospectively analyzed the data of 75 patients with EGFR-mutated NSCLC and LM and stratified them into three groups based on EGFR-Tyrosine Kinase Inhibitor (TKI) treatment history. The median overall survival (OS) after LM diagnosis was 12.2 months, with patients who had not received prior EGFR-TKI treatment having longer OS compared to those who developed LM after EGFR-TKI resistance. <br /><br />The study found that intrathecal chemotherapy improved the OS of the patients, while whole-brain radiation therapy did not. Inferior Eastern Cooperative Oncology Group Performance Status (ECOG PS) and baseline magnetic resonance imaging (MRI) positive findings were identified as independent predictors for OS. <br /><br />Patients who received third-generation EGFR-TKI combined treatment after LM diagnosis had an objective response rate (ORR) of 45.2% and a disease control rate (DCR) of 76.7%. Although not statistically significant, combined treatment and high-dose third-generation EGFR-TKI showed superior OS across the three groups. Additionally, patients in Group 2 who received bevacizumab along with third-generation EGFR-TKI had longer OS compared to those without bevacizumab. <br /><br />In conclusion, high-dose third-generation EGFR-TKI is an effective treatment for NSCLC patients with EGFR mutation and LM. Intrathecal chemotherapy and third-generation EGFR TKI plus bevacizumab are expected to improve OS in these patients.

Asset Subtitle

Yun Fan

Meta Tag

Speaker Yun Fan

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

epidermal growth factor receptor

NSCLC

leptomeningeal metastasis

EGFR-TKI

intrathecal chemotherapy

ECOG PS

MRI

bevacizumab

third-generation EGFR-TKI